TabsDetailsBasic DetailsDate: Monday, October 6, 2014Type: PublicationMedical Product: aripiprazole, olanzapine, quetiapine, risperidone, second generation antipsychotic (SGA)Health Outcome(s): baseline glucose assessmentDescription: This article describes the findings of a study conducted to evaluate baseline glucose assessment among youth ages 2 through 18 starting a second-generation antipsychotic in the United States. Read More Materials: Pediatrics, Volume 135, Issue 5, October 6, 2014, Pages e1308-1314, DOI: 10.1542/peds.2014-0828Additional InformationInformationTime Period: 2006 - 2011Population / Cohort: All children 2 through 18 years of ageData Source(s): Mini-Sentinel Distributed Database (MSDD)Related Assessment(s): Final Report: Metabolic Effects Of Second Generation Antipsychotics In YouthContributorsAuthor(s): Marsha Raebel PharmD; Robert Penfold PhD; Ann McMahon MD, MSc; Marsha Reichman PhD; Susan Shetterly MS; Glenn Goodrich MS; Susan Andrade ScD; Christoph Correll MD; Tobias Gerhard PhDCorresponding Author: Marsha Raebel, Institute for Health Research, Kaiser Permanente Colorado, PO Box 378066, Denver, CO 80237, USA. Email: Marsha.A.Raebel@kp.org
